Cargando…

Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations

Background: Recent trials support the clinical efficacy and safety of subcutaneous infliximab (IFX) or vedolizumab (VDZ) for Inflammatory Bowel Disease (IBD). We evaluated the uptake and rationale for choosing to switch from intravenous infusions to subcutaneous injections. Methods: Retrospective an...

Descripción completa

Detalles Bibliográficos
Autores principales: Burdge, Gemma, Hardman, Alice, Carbery, Isabel, Broglio, Giacomo, Greer, Dan, Selinger, Christian P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571673/
https://www.ncbi.nlm.nih.gov/pubmed/36233537
http://dx.doi.org/10.3390/jcm11195669
_version_ 1784810420913045504
author Burdge, Gemma
Hardman, Alice
Carbery, Isabel
Broglio, Giacomo
Greer, Dan
Selinger, Christian P.
author_facet Burdge, Gemma
Hardman, Alice
Carbery, Isabel
Broglio, Giacomo
Greer, Dan
Selinger, Christian P.
author_sort Burdge, Gemma
collection PubMed
description Background: Recent trials support the clinical efficacy and safety of subcutaneous infliximab (IFX) or vedolizumab (VDZ) for Inflammatory Bowel Disease (IBD). We evaluated the uptake and rationale for choosing to switch from intravenous infusions to subcutaneous injections. Methods: Retrospective analysis of all adult patients receiving standard dosing IFX or VDZ maintenance therapy to investigate uptake of subcutaneous injections and the rationale for switching to subcutaneous injections. Results: Of 232 eligible patients (total = 258: IFX = 190, VDZ = 68, and no longer eligible = 26), 58% of patients on IFX and 59% of patients on VDZ chose to switch to subcutaneous treatment. Age, sex, diagnosis, drug, line of treatment, and duration of treatment were not predictors for willingness to switch. Questionnaire responses (n = 51) demonstrate that the decision to switch was not influenced by COVID-19 exposure risk, impact on wider IBD service provision, impact on patient mental health, financial savings, seeking support following a switch, or a sense of independence managing IBD. Switchers (68%) were more motivated by time savings than non-switchers (25%; p = 0.0042). Conclusions: Switch uptake rates were 58%, with 90% of patients eligible to switch. Switch decision was influenced by time savings for patients but not by other patient-related factors.
format Online
Article
Text
id pubmed-9571673
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95716732022-10-17 Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations Burdge, Gemma Hardman, Alice Carbery, Isabel Broglio, Giacomo Greer, Dan Selinger, Christian P. J Clin Med Article Background: Recent trials support the clinical efficacy and safety of subcutaneous infliximab (IFX) or vedolizumab (VDZ) for Inflammatory Bowel Disease (IBD). We evaluated the uptake and rationale for choosing to switch from intravenous infusions to subcutaneous injections. Methods: Retrospective analysis of all adult patients receiving standard dosing IFX or VDZ maintenance therapy to investigate uptake of subcutaneous injections and the rationale for switching to subcutaneous injections. Results: Of 232 eligible patients (total = 258: IFX = 190, VDZ = 68, and no longer eligible = 26), 58% of patients on IFX and 59% of patients on VDZ chose to switch to subcutaneous treatment. Age, sex, diagnosis, drug, line of treatment, and duration of treatment were not predictors for willingness to switch. Questionnaire responses (n = 51) demonstrate that the decision to switch was not influenced by COVID-19 exposure risk, impact on wider IBD service provision, impact on patient mental health, financial savings, seeking support following a switch, or a sense of independence managing IBD. Switchers (68%) were more motivated by time savings than non-switchers (25%; p = 0.0042). Conclusions: Switch uptake rates were 58%, with 90% of patients eligible to switch. Switch decision was influenced by time savings for patients but not by other patient-related factors. MDPI 2022-09-26 /pmc/articles/PMC9571673/ /pubmed/36233537 http://dx.doi.org/10.3390/jcm11195669 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Burdge, Gemma
Hardman, Alice
Carbery, Isabel
Broglio, Giacomo
Greer, Dan
Selinger, Christian P.
Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations
title Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations
title_full Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations
title_fullStr Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations
title_full_unstemmed Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations
title_short Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations
title_sort uptake of a switching program for patients receiving intravenous infliximab and vedolizumab to subcutaneous preparations
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571673/
https://www.ncbi.nlm.nih.gov/pubmed/36233537
http://dx.doi.org/10.3390/jcm11195669
work_keys_str_mv AT burdgegemma uptakeofaswitchingprogramforpatientsreceivingintravenousinfliximabandvedolizumabtosubcutaneouspreparations
AT hardmanalice uptakeofaswitchingprogramforpatientsreceivingintravenousinfliximabandvedolizumabtosubcutaneouspreparations
AT carberyisabel uptakeofaswitchingprogramforpatientsreceivingintravenousinfliximabandvedolizumabtosubcutaneouspreparations
AT brogliogiacomo uptakeofaswitchingprogramforpatientsreceivingintravenousinfliximabandvedolizumabtosubcutaneouspreparations
AT greerdan uptakeofaswitchingprogramforpatientsreceivingintravenousinfliximabandvedolizumabtosubcutaneouspreparations
AT selingerchristianp uptakeofaswitchingprogramforpatientsreceivingintravenousinfliximabandvedolizumabtosubcutaneouspreparations